Latest H5N1 clinical trials Stories
ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc.
The WHO said on Tuesday that GlaxoSmithKline recalled a batch of swine flu vaccine in Canada after a number of severe allergic reactions surfaced.
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) on Monday voiced concerns about the sluggish vaccination rate for the H1N1 swine flu due to public skepticism over health risks and side effects.
ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico.
SWIFTWATER, Pa., Nov. 11 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the final analyses of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults and children.
ROCKVILLE, Md., Nov. 11 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances, will be presenting at the Influenza Congress USA 2009. Mr.
ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) has begun a Phase IIa clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older.
GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc.
Pivotal testing of RTS,S is on track for target enrollment of 16,000 children.
ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Novavax, Inc.